StemCells, Inc. has announced completion of the first planned interim safety review of the company’s Phase I/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated. The trial, which is designed to evaluate the safety and preliminary efficacy of the their proprietary HuCNS-SC® cells, represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury.
StemCells, Inc. reports positive interim safety data from spinal cord injury trial
Skip back to main navigation